Multicenter, randomized, controlled trial of S‐1 monotherapy versus S‐1 and interferon‐α combination therapy for hepatocellular carcinoma with extrahepatic metastases

Aim No effective therapies for extrahepatic metastases from hepatocellular carcinoma (HCC) have yet been identified. Previous studies suggested a potentially promising antitumor effect of combination therapy of S‐1, a novel oral dihydropyrimidine dehydrogenase inhibitor, and interferon (IFN)‐α. The...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology research 2018-08, Vol.48 (9), p.717-726
Hauptverfasser:	Nagano, Hiroaki, Obi, Shuntaro, Hatano, Etsuro, Kaneko, Shuichi, Kanai, Fumihiko, Omata, Masao, Tsuji, Akihito, Itamoto, Toshiyuki, Yamamoto, Kazuhide, Tanaka, Masatoshi, Kubo, Shoji, Hirata, Koichi, Nakamura, Hideji, Tomimaru, Yoshito, Yamanaka, Takeharu, Kojima, Shinsuke, Monden, Morito
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitumor activity Hepatocellular carcinoma Interferon Liver cancer Metastases Metastasis Patients randomized controlled trial Survival S‐1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!